ERBB2 and breast carcinoma: These subtypes have shown prognostic value in patients with early-stage and metastatic HR+/HER2- breast cancer and predict response to endocrine therapy in combination with CDK4/6 inhibition in patients with metastatic HR+/HER2- breast cancer18.